BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.